Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by SlateStone Wealth LLC

SlateStone Wealth LLC lessened its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 25.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,825 shares of the medical research company’s stock after selling 1,626 shares during the period. SlateStone Wealth LLC’s holdings in Thermo Fisher Scientific were worth $2,561,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of TMO. International Assets Investment Management LLC boosted its position in shares of Thermo Fisher Scientific by 43.5% during the 3rd quarter. International Assets Investment Management LLC now owns 1,626 shares of the medical research company’s stock valued at $810,000 after purchasing an additional 493 shares in the last quarter. Arkadios Wealth Advisors boosted its position in shares of Thermo Fisher Scientific by 33.3% during the 3rd quarter. Arkadios Wealth Advisors now owns 896 shares of the medical research company’s stock valued at $454,000 after purchasing an additional 224 shares in the last quarter. Wedge Capital Management L L P NC boosted its position in shares of Thermo Fisher Scientific by 8.3% during the 3rd quarter. Wedge Capital Management L L P NC now owns 740 shares of the medical research company’s stock valued at $375,000 after purchasing an additional 57 shares in the last quarter. Summit Global Investments boosted its position in shares of Thermo Fisher Scientific by 27.8% during the 3rd quarter. Summit Global Investments now owns 1,392 shares of the medical research company’s stock valued at $704,000 after purchasing an additional 303 shares in the last quarter. Finally, RFG Advisory LLC boosted its position in shares of Thermo Fisher Scientific by 13.2% during the 3rd quarter. RFG Advisory LLC now owns 2,838 shares of the medical research company’s stock valued at $1,436,000 after purchasing an additional 332 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Up 1.1 %

NYSE TMO traded up $6.60 during trading on Wednesday, reaching $581.19. 326,748 shares of the stock traded hands, compared to its average volume of 1,546,730. The stock’s 50-day moving average price is $572.03 and its 200 day moving average price is $528.72. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67. The firm has a market cap of $221.85 billion, a price-to-earnings ratio of 37.22, a price-to-earnings-growth ratio of 2.31 and a beta of 0.80. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, topping analysts’ consensus estimates of $5.64 by $0.03. The business had revenue of $10.89 billion for the quarter, compared to analyst estimates of $10.73 billion. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The firm’s revenue for the quarter was down 4.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $5.40 earnings per share. Analysts predict that Thermo Fisher Scientific Inc. will post 21.51 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were given a dividend of $0.39 per share. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a yield of 0.27%. The ex-dividend date was Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio is 10.10%.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the sale, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at $7,250,362. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the transaction, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the completion of the transaction, the chief executive officer now owns 49,155 shares in the company, valued at $27,311,992.65. The disclosure for this sale can be found here. Over the last three months, insiders have sold 50,277 shares of company stock valued at $28,513,384. 0.32% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Barclays cut shares of Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and raised their target price for the stock from $475.00 to $555.00 in a report on Wednesday, January 24th. Royal Bank of Canada raised their price target on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Evercore ISI raised their price target on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. Citigroup assumed coverage on shares of Thermo Fisher Scientific in a report on Monday, March 18th. They set a “neutral” rating and a $620.00 price target for the company. Finally, The Goldman Sachs Group raised their price target on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Five analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $604.69.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.